Pilulka's Market Expansion and Innovation

2 USE OF PROCEEDS 65 Market share increase on foreign markets In 2022, Pilulka entered Austria and Hungary with an ambition to become the market leader among online pharmacies and the best mobile pharmacy and drugstore on those markets. Both Austrian and Hungarian markets have great potential, which has not yet been fully harnessed by local players. Following the successful completion of the SPO, Pilulka plans to accelerate its expansion there through a less capital intensive hybrid model, which is combining the Company's current infrastructure with local commercial department and customer care. Like in the Czech Republic and Slovakia, Pilulka will introduce a distinctly customer-centric approach on these markets, and offer innovative and reliable services, including the Pilulka Express delivery service and its own network of dispensing boxes Development of e-health initiatives Pilulka is a digital platform connecting pharmaceutical companies, distributors, health insurance companies and healthcare providers with end-customers. In addition to the sale of drugs and other goods, Pilulka is creating entirely new business verticals, focused on prevention, the efficient transfer of information between health insurance companies and their clients, easy and fast search for medical care, and the development of digital tools that allow leading pharmaceutical companies to monitor the treatment of chronically ill patients. Also, within Pilulka Lab, the Company's own start-up accelerator, Pilulka aims to capture and leverage modern trends in healthcare. These and other e-health initiatives represent the future of healthcare and Pilulka will focus on developing them further Strengthening of working capital In the context of accelerated international development, Pilulka's working capital and especially inventory will need to be strengthened further. The expansion into new markets also offers new opportunities in terms of supply chain and sourcing, including central purchases on a larger scale and the strengthening of the own private label portfolio, the increased sales of which will have a direct positive impact on Pilulka's profitability Opportunistic acquisitions in the Czech Republic and abroad Ample room for the further consolidation of the Central European pharmacy market, combined with the Company's proven business model and an experienced management team, are key enablers that will allow Pilulka to continue its solid organic growth, while presenting an opportunity for inorganic growth through acquisitions and mergers with other players 6 +pilulka

View entire presentation